BA
ASND icon

BlackRock Advisors’s Ascendis Pharma A/S ASND Stock Holding History

BlackRock Advisors’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-131,300
Closed -$2.28M – 3713
2015
Q1 		$2.28M Buy
+131,300
New +$2.39M ﹤0.01% 1174

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

BlackRock Advisors's ASND Position: Q2 2015 in Review

BlackRock Advisors sold out of Ascendis Pharma A/S (ASND) in Q2 2015, closing a stake of 131,300 shares — an estimated $2.28M sold.

BlackRock Advisors first reported a position in ASND in Q1 2015 and held it in 1 quarter. The position peaked at $2.28M in Q1 2015. 33 funds tracked by Wall St. Rank hold ASND as of Q2 2015.

  • BlackRock Advisors reported no remaining Ascendis Pharma A/S position as of Q2 2015 after selling out during the quarter.
  • BlackRock Advisors sold 131,300 Ascendis Pharma A/S shares in Q2 2015, an estimated $2.28M.
  • BlackRock Advisors first reported a position in Ascendis Pharma A/S in Q1 2015 and held it in 1 quarter.
  • BlackRock Advisors's Ascendis Pharma A/S position peaked at $2.28M in Q1 2015.
  • 33 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2015.

Based on BlackRock Advisors's 13F filing for Q2 2015, filed 7 Aug 2015.